文献速递消化系统肿瘤

多纳非尼对比索拉非尼一线治疗不可切除或转移性肝细胞癌:随机、开放、平行对照II-III期试验

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
PubMed 文献 · J Clin Oncol · 2021-06-29

该开放、随机、平行对照、多中心II-III期试验纳入中国37个中心668例不可切除或转移性肝细胞癌患者,随机接受多纳非尼或索拉非尼一线治疗。

要点

  • 多纳非尼一线治疗中国晚期肝细胞癌,总生存期优于索拉非尼。
  • 多纳非尼≥3级药物相关不良事件发生率显著低于索拉非尼。
  • 无进展生存期、客观缓解率和疾病控制率两组无显著差异。

核心结论

  • 在中国晚期肝细胞癌患者中,多纳非尼一线治疗的总生存期优于索拉非尼,且安全性和耐受性良好。

研究设计与样本

  • 开放、随机、平行对照、多中心II-III期试验,自中国37个中心入组不可切除或转移性肝细胞癌患者。
  • 入组标准为Child-Pugh评分≤7且未接受过系统治疗,按1:1随机接受口服多纳非尼0.2g或索拉非尼0.4g每日两次。
  • 主要终点为总生存期,检验非劣效性和优效性;疗效主要在全分析集评估,安全性在所有治疗患者中评估。

主要发现

  • 意向治疗人群中多纳非尼同样显示总生存期优于索拉非尼。

临床怎么用

  • 对于Child-Pugh评分≤7且未接受系统治疗的中国不可切除或转移性肝细胞癌患者,多纳非尼可作为一线单药治疗选择。

局限性

  • 研究仅纳入中国患者,结论外推至其他人群需谨慎。
  • 试验为开放标签设计,可能影响部分主观终点的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC. PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤ 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients. RESULTS: Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months (P = .0570). The objective response rate was 4.6% v 2.7% (P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade ≥ 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018). CONCLUSION: Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Qin S, Bi F, Gu S, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol. 2021. PMID: 34185551. doi:10.1200/JCO.21.00163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。